Wave Life Sciences ​shares plunged 58% on Thursday after a higher dose of its experimental obesity ‌drug failed to show a clear improvement at reducing a dangerous type of belly fat.

Wave Life Sciences (WVE) stock plunges as the company interim data from an early-stage trial for WVE-007, its RNA-based obesity medicine. Read more here.

On March 26, 2026, traders mulled Wave's weak high-dose obesity results against the company's large market opportunity.

Wave Life Sciences shares plunged >50% after Phase 1 INLIGHT data for WVE-007 showed <1% placebo-adjusted weight loss at six months. Find out why WVE is a Hold.

Read about the new Biocom Octane partnership. Discover how this collaboration expands capital and accelerator access for ...

Wave Life Sciences stock crashed Thursday after the company's much-hyped "body composition" drug led to just 1% weight loss in six months.

W hile challenges persist in the short term, there are signs pointing toward long-term growth for life sciences, according to JLL’s 2024 Life Sciences Real Estate Perspective and Cluster Analysis. The ...

The American Association for the Advancement of Science, AAAS, bestowed the title of AAAS Fellow upon Bradford Wilcox, Ph.D., ...

Like the lead character of “Project Hail Mary,” some scientists are proposing ways that life might exist beyond a star’s ...

Dr. Mark Turco "will step down" from his role with the Hub Wednesday, March 11, to lead a medical device company.